{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:48:34Z","timestamp":1788670114881,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.lungcan.2025.108786","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:05:55Z","timestamp":1759460755000},"page":"108786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6030-3687","authenticated-orcid":false,"given":"V.","family":"Andreas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-810X","authenticated-orcid":false,"given":"M.","family":"Faltys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5782-7912","authenticated-orcid":false,"given":"M.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Parakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9317-5026","authenticated-orcid":false,"given":"S.","family":"Bowyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-1596","authenticated-orcid":false,"given":"L.","family":"Warburton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2703-4150","authenticated-orcid":false,"given":"A.","family":"Fantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1953-2694","authenticated-orcid":false,"given":"T.","family":"Clay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Arulananda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9340-8392","authenticated-orcid":false,"given":"L.J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.G.M.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Itchins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lungcan.2025.108786_b0005","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.21.01881","article-title":"Extensive-stage small-cell lung cancer: first-line and second-line treatment options","volume":"40","author":"Zugazagoitia","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108786_b0010","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.mayocp.2019.01.034","article-title":"Current diagnosis and management of small-cell lung cancer","volume":"94","author":"Wang","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.lungcan.2025.108786_b0015","article-title":"Emerging strategies for the treatment of small cell lung cancer: a review. JAMA","author":"Petty","year":"2022","journal-title":"Oncol"},{"key":"10.1016\/j.lungcan.2025.108786_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.840783","article-title":"SCLC treatment in the immuno-oncology era: current evidence and unmet needs","volume":"12","author":"Belluomini","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2025.108786_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1161931","article-title":"Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting","volume":"13","author":"Sands","year":"2023","journal-title":"Front. Oncol."},{"issue":"23","key":"10.1016\/j.lungcan.2025.108786_b0030","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.lungcan.2025.108786_b0035","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108786_b0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12032-018-1123-6","article-title":"Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer","volume":"35","author":"Naito","year":"2018","journal-title":"Med. Oncol."},{"key":"10.1016\/j.lungcan.2025.108786_b0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.lungcan.2020.03.024","article-title":"Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - a decision-making analysis amongst European lung cancer experts","volume":"146","author":"Fr\u00fch","year":"2020","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2025.108786_b0050","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1158\/1078-0432.CCR-20-3901","article-title":"FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer","volume":"27","author":"Singh","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108786_b0055","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccm.2011.07.002","article-title":"Current management of small cell lung cancer","volume":"32","author":"Neal","year":"2011","journal-title":"Clin. Chest Med."},{"issue":"34","key":"10.1016\/j.lungcan.2025.108786_b0060","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1200\/JCO.2006.06.5821","article-title":"Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer","volume":"24","author":"O'Brien","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108786_b0065","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"von Pawel","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108786_b0070","first-page":"645","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"LancetOncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108786_b0075","first-page":"74","article-title":"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial","volume":"11","author":"Aix","year":"2023","journal-title":"LancetRespir. Med."},{"key":"10.1016\/j.lungcan.2025.108786_b0080","doi-asserted-by":"crossref","first-page":"ix176","DOI":"10.1093\/annonc\/mdz437.049","article-title":"A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: a prospective study from a south Indian tertiary cancer hospital","volume":"30","author":"Moharana","year":"2019","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108786_b0085","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/oncolo\/oyae234","article-title":"Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer","volume":"29","author":"Shaw","year":"2024","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108786_b0090","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108786_b0095","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","article-title":"Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"112","author":"Schvartsman","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108786_b0100","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.semcancer.2022.02.021","article-title":"Evolving role of immunotherapy in small cell lung cancer","volume":"86","author":"Barrows","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108786_b0105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/JTO.0000000000000385","article-title":"Relevance of platinum-sensitivity status in relapsed\/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials","volume":"10","author":"Lara","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108786_b0110","first-page":"1224","article-title":"Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial","volume":"21","author":"Baize","year":"2020","journal-title":"LancetOncol."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108786_b0115","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.21037\/tlcr-20-362","article-title":"Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined","volume":"9","author":"Choua\u00efd","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108786_b0120","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2022-0098","article-title":"Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer","volume":"12","author":"Hanvesakul","year":"2023","journal-title":"J. Comp. Eff. Res."},{"issue":"15","key":"10.1016\/j.lungcan.2025.108786_b0125","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1111\/1759-7714.14464","article-title":"Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice","volume":"13","author":"Toublanc","year":"2022","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.lungcan.2025.108786_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107887","article-title":"Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: a large French multicenter study","volume":"194","author":"Pons-Tostivint","year":"2024","journal-title":"Lung Cancer"},{"issue":"22","key":"10.1016\/j.lungcan.2025.108786_b0135","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108786_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2024.12.028","article-title":"Phase 2 open-label study of Sacituzumab Govitecan as second-line therapy in patients with extensive-stage SCLC: results from TROPiCS-03","author":"Dowlati","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108786_b0145","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jtho.2025.02.005","article-title":"Lurbinectedin plus pembrolizumab in relapsed SCLC: the phase I\/II LUPER study","volume":"20","author":"Calles","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"10495","key":"10.1016\/j.lungcan.2025.108786_b0150","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108786_b0155","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","article-title":"Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331(\u2606)","volume":"32","author":"Spigel","year":"2021","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108786_b0160","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","article-title":"Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies","volume":"15","author":"Chung","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108786_b0165","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.cllc.2012.12.003","article-title":"Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study","volume":"14","author":"Spigel","year":"2013","journal-title":"Clin. Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T04:46:52Z","timestamp":1762490812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225006786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":33,"alternative-id":["S0169500225006786"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108786","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108786","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108786"}}